We use intelligence, data and analysis to support healthcare systems by tracking emerging threats, enabling us to be in a position to offer healthcare professionals, governments, individuals and organisations exactly what they need when it’s needed most.
We are informed by expert input from healthcare professionals and scientists as well as global surveillance systems. By identifying needs and trends early we can allocate resources ensuring we have reliable solutions to meet expected demand.
This approach underpins our commitment to being a ‘global first responder’ in the fight against infectious diseases and our agility has allowed us to bring this offering to life.
Novacyt will continue to invest in R&D in order to deliver new products in
We convene scientific and therapeutic advisory boards on international and domestic levels. Together with our surveillance mechanisms, these will assist the business with scientific guidance to direct our future innovations.
We are also considering additional unmet needs in infectious diseases including sexually transmitted infections (STI), urinary tract infections (UTI), hospital acquired infections, meningitis/encephalitis and sepsis.
Novacyt S.A. (“Novacyt”, the “Company” or the “Group”) Long Term Incentive Plan 2024 Performance Share Awards Paris, France, and Eastleigh and Manchester, UK – 23 April 2024 – Novacyt S.A.......
Novacyt S.A. (“Novacyt”, the “Company” or the “Group”) DHSC Claim update – Pre-Trial Review Paris, France, and Eastleigh and Manchester, UK – 19 April 2024 – Novacyt S.A. (EURONEXT GROWTH:......
Novacyt S.A. (“Novacyt”, the “Company” or the “Group”) Directorate changes and full year 2023 results update Lyn Rees appointed CEO Dr. Joanne Mason, CSO, to join the Board Paris, France,......
Novacyt S.A. (“Novacyt”, the “Company” or the “Group”) Update on Taiwanese divestment Paris, France, and Eastleigh and Manchester, UK – 6 February 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM:......
New freeze-dried, direct-to-PCR assays extend the global reach of Novacyt’s PCR portfolio with ability to be transported at ambient temperatures Two PROmate® lyophilised assays initially launched for COVID-19, with a......
The assay has been developed by Novacyt to support research efforts following a recent increase in cases of acute hepatitis in children Paris, France and Camberley, UK – 28 July......
Paris, France and Camberley, UK – 20 July 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that all resolutions proposed at the ordinary......
Paris, France and Camberley, UK – 15 July 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on......
Paris, France and Camberley, UK – 15 July 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s exsig™ COVID-19 Direct Real-Time......
Paris, France and Camberley, UK – 7 July 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces a trading update for the half year......
Paris, France and Camberley, UK – 5 July 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified by Biosynex......
Paris, France and Camberley, UK – 21 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual General Meeting (AGM),......
Paris, France and Camberley, UK – 16 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with......
Paris, France and Camberley, UK – 13 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM)......
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual Report and Accounts (“Annual Report”) for the year ended 31 December 2021 has......
Novacyt has unveiled the new CO-Prep™ Automated Liquid Handling System designed for use with the PROmate® COVID-19 assay workflows, which can also be used to support busy laboratories and private......
Winter 2021/2022 could become the most challenging in decades for respiratory healthcare. There are many unknowns, such as the potential impact of circulating influenza or the trajectory of new COVID-19......
As international travel begins to re-open following the challenges of the COVID-19 pandemic, there’s a growing need for reliable, high-quality tests to satisfy the border requirements of different countries. The......
The costs and healthcare challenges of tackling COVID-19 have threatened the world’s ability to address a steady rise in other serious infectious diseases. That’s the conclusion of a panel of......
The growth of the COVID-19 pandemic globally over the past 18 months has been exponential, and despite mitigating measures and the vaccine roll-out, the virus continues to mutate and spread.......
A multi-layered approach comprising vaccines, testing, lockdowns where necessary and medication will be essential for the foreseeable future in combatting COVID-19 – described as an “extraordinarily transmissible virus,” during the......
Market-leading intelligence is the catalyst behind Novacyt’s ability to anticipate – and respond – to emerging new SARS-CoV-2 variants. Global tracking of virus mutations enables its R & D division......
Advancing technology and a unique wealth of knowledge are the driving forces behind innovative development in our PathFlow® portfolio of diagnostic tests for infectious diseases. Our latest addition to the......
PathFlow®: Future innovation of COVID-19 Lateral Flow Testing Advancing technology and a unique wealth of knowledge are the driving forces behind innovative development in our PathFlow® portfolio of diagnostic tests......
The advances in testing and genome sequencing during the COVID-19 pandemic will be crucial to predicting and managing future pandemics, according to scientific discussion during the NovaTalk webinar on February......
SARS-CoV-2 Mutations – Cause for Concern? The accumulation of genetic mutations is a normal part of viral evolution. Mutations change the sequence of the viral genome, creating different ‘variants.’ While......
SARS-CoV-2 Mutations – Cause for Concern? The accumulation of genetic mutations is a normal part of viral evolution. Mutations change the sequence of the viral genome, creating different ‘variants.’ While......
Learn more about our range of COVID-19 solutions and how they could help with your diagnostic needs. As we enter 2021, we also move into a new phase of the......
What does the emergence of new SARS-CoV-2 variants mean for testing? The UK has recently been at the centre of considerable media attention due to the detection of a large......
Despite the introduction of protective measures, the COVID-19 pandemic has continued to take hold across the world. The latest data from the World Health Organisation indicates that over 40 million......
Distinguishing COVID-19 infection from other respiratory illnesses is of crucial importance in controlling the spread of the disease. This is especially true during the winter months, where there is a......
Welcome back to the latest blog! As we edge closer to the winter season. This year will be a pivotal time for testing compared to previous years. Each year during......
Novacyt’s Near-Patient Test System (NPTS) for COVID-19 Introduction The value of testing for COVID-19 is well documented not only in the UK, but globally as we reflect on how the......
Hello! Welcome back to our latest blog. All departments have been working tirelessly to find an innovative solution following the bottle-neck of scarce raw materials that clinicians require to test. ......
We are proud to have launched exsig™ a family of extraction workflow products tailored to suit your requirements in testing. exsig™ is a product range like no other consisting of various......
Welcome to our latest blog! There have been many changes since our last blog, worldwide and within the company, our strong commitment to support testing remains. Since our last update,......
In this blog, we take a look at technical design problems with primer/probes if not designed to the standard required. The design process is a pivotal part of the process......
In light of recent events unfolding in China with the outbreak of Coronavirus (2019-nCoV) spreading across to other countries with over 17,000 infected and over 550 fatalities, Primerdesign has launched......
Welcome to our latest blog! If you are reading this and want to learn more about our high-quality master mixes, you have come to the right place! Our ISO approved......
What is Listeria? Listeria monocytogenes (genus listeria) is a bacterium illness that causes listeriosis. Listeria can be found in unpasteurised milk, dairy products, soft cheeses (camembert or brie) and chilled ready to......
Extension of contract continues multi-year assay design and development program Paris, France and Camberley, UK – 8 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in......
Paris, France and Camberley, UK – 26 February 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that through its molecular testing subsidiary, Primerdesign,......
genesig® Real-Time PCR BKV Kit (CE), and genesig® Real-Time PCR EBV Kit (CE) The new molecular kits have been developed to provide quantitative detection of viral DNA extracted from blood......
Fast and accurate direction of ASFV infection in pigs, including emerging strain ASFV-SY18 African swine fever virus (ASFV) causes haemorrhagic fever in pigs that leads to high mortality rates in......
First of an expanding menu of tests for monitoring post-transplantation and immunosuppressed patients Paris, France and Camberley, UK – 21 December 2018: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international......
Completion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market Paris, France and Camberley, UK – 6th December 2018 – Novacyt (EURONEXT GROWTH: ALNOV;......
US partnership to facilitate the design and optimisation for customised microarray assays Paris, France and Camberley, UK – 13 September 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international......
New research* released today shows that little progress may have been made since the last food scandal in 2013. Out of 665 results from England, Wales and Northern Ireland collected......
Accelerating profitability by expanding the Lab21 business with complimentary products Paris, France and Camberley, UK – 28th June 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in......
Quality is paramount to Primerdesign’s success and reputation. It is critical that customers are confident in the quality and performance of our products. By promoting a culture of improvement, accountability......
Primerdesign is proud to present three brand new real-time PCR product ranges to our portfolio. Firstly, genesigMYPLEX qPCR Kit STD is a personalised approach to multiplex assays. You have full......
Japanese Encephalitis Virus (JEV) is relatively unknown, even though it has been the leading cause of viral encephalitis in Asia for the last 20 years. The disease is a mosquito-borne......
Our webinar series on diagnostics and infectious diseases can be viewed here. Hear expert views on COVID-19 and other issues in infectious diseases.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
